SCHEMBL12848955

SCHEMBL12848955

Cc1noc(C)c1NC(=O)c1cc2c(s1)-c1cc(-c3cccnc3)ccc1CCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
TDP1 Q9NUW8 1/20 0.41
BRAF P15056 1/20 0.41
NPC1 O15118 4/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
BRD4 O60885 2/20 0.37
ALDH1A1 P00352 3/20 0.37
RAB9A P51151 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 1/20 0.37
ALOX5AP P20292 1/20 0.37
CREBBP Q92793 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NOTUM Q6P988 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12848727 0.83 MEN1 (0.42) MEN1KMT2ATDP1NPC1CYP11B1
SCHEMBL12848433 0.83 MEN1 (0.42) MEN1KMT2ATDP1NPC1CYP11B1
SCHEMBL12848481 0.83 MEN1 (0.42) MEN1KMT2ATDP1BRAFNPC1
SCHEMBL12848730 0.82 MEN1 (0.42) MEN1KMT2ATDP1NPC1CYP11B1
SCHEMBL12848824 0.82 MEN1 (0.48) MEN1KMT2ATDP1NPC1CYP11B1
SCHEMBL12848731 0.81 DYRK1A (0.47) MEN1KMT2ATDP1NPC1CYP11B1
SCHEMBL12848962 0.80 MEN1 (0.40) MEN1KMT2ATDP1BRAFNPC1
SCHEMBL12848881 0.79 ABCB1 (0.48) MEN1KMT2ATDP1NPC1CYP11B1
SCHEMBL12848728 0.79 KDM4E (0.50) MEN1KMT2ATDP1NPC1CYP11B1
SCHEMBL12848440 0.78 DYRK1A (0.50) CYP11B1CYP11B2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES TSLP, NFATC1, IL5 MEN1 4414/4885KMT2A 3424/4885TDP1 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.